^
    Back
    Association details:
    Biomarker:TP53 -181_-179delAAA
    Cancer:Chronic Myeloid Leukemia
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2020
    Title:

    IDENTIFICATION OF GENOMIC VARIANTS ASSOCIATED WITH LONG TERM MOLECULAR RESPONSE TO TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA

    Published date:
    05/14/2020
    Excerpt:
    Novel genes/variants associated exclusively with long-term CML responders to imatinib and absent in all control groups, namely PTPN22, TTN, PDLIM4, CACNA1B, CELF2, ANO5,MYO16,TP53,KCNJ12 and RAI1 genes...